Journal of Molecular and Cellular Cardiology
Volume 48, Issue 6 , Pages 1088-1095 , June 2010

Beta 3-adrenoreceptor regulation of nitric oxide in the cardiovascular system

  • An L. Moens

      Affiliations

    • Johns Hopkins University School of Medicine, Div. of Cardiology, Baltimore, MD, USA
    • Cardiovascular Research Institute Maastricht, University of Maastricht, Maastricht, The Netherlands
    • These authors contributed equally to this work.
    • ,
  • Ronghua Yang

      Affiliations

    • Johns Hopkins University School of Medicine, Div. of Cardiology, Baltimore, MD, USA
    • These authors contributed equally to this work.
    • ,
  • Vabren L. Watts

      Affiliations

    • Johns Hopkins University School of Medicine, Div. of Cardiology, Baltimore, MD, USA
    • ,
  • Lili A. Barouch

      Affiliations

    • Johns Hopkins University School of Medicine, Div. of Cardiology, Baltimore, MD, USA
    • Corresponding Author InformationCorresponding author. Johns Hopkins Medical Institutions, Div. of Cardiology, Ross Research Building 1050, 720 Rutland Ave, Baltimore, MD, 21205, USA. Tel.: +1 410 502 0188; fax: +1 410 614 0384.

Received 20 July 2009 ,Revised 8 December 2009 ,Accepted 12 February 2010.

References 

  1. Kaumann AJ, Engelhardt S, Hein L, Molenaar P, Lohse M. Abolition of (−)-CGP 12177-evoked cardiostimulation in double beta1/beta2-adrenoceptor knockout mice. Obligatory role of beta1-adrenoceptors for putative beta4-adrenoceptor pharmacology. Naunyn Schmiedebergs Arch Pharmacol. 2001;363:87–93
  2. Rouget C, Bardou M, Breuiller-Fouche M, Loustalot C, Qi H, Naline E, et al. Beta3-adrenoceptor is the predominant beta-adrenoceptor subtype in human myometrium and its expression is up-regulated in pregnancy. J Clin Endocrinol Metab. 2005;90:1644–1650
  3. Gauthier C, Langin D, Balligand JL. Beta3-adrenoceptors in the cardiovascular system. Trends Pharmacol Sci. 2000;21(11):426–431
  4. Gauthier C, Tavernier G, Charpentier F, Langin D, Le Marec H. Functional beta3-adrenoceptor in the human heart. J Clin Invest. 1996;98:556–562
  5. Moniotte S, Kobzik L, Feron O, Trochu JN, Gauthier C, Balligand JL. Upregulation of beta(3)-adrenoceptors and altered contractile response to inotropic amines in human failing myocardium. Circulation. 2001;103:1649–1655
  6. Daaka Y, Luttrell LM, Lefkowitz RJ. Switching of the coupling of the beta2-adrenergic receptor to different G proteins by protein kinase A. Nature. 1997;390:88–91
  7. Liggett SB, Freedman NJ, DA S, Lefkowitz RJ. Structural basis for receptor subtype-specific regulation revealed by a chimeric beta 3/beta 2-adrenergic receptor. Proc Natl Acad Sci USA. 1993;90:3665–3669
  8. Soeder KJ, Snedden SK, Cao W, Della Rocca GJ, Daniel KW, Luttrell LM, et al. The beta3-adrenergic receptor activates mitogen-activated protein kinase in adipocytes through a Gi-dependent mechanism. J Biol Chem. 1999;274:12017–12022
  9. Emorine LJ, Marullo S, Briend-Sutren MM, Patey G, Tate K, Delavier-Klutchko C, et al. Molecular characterization of the human beta 3-adrenergic receptor. Science. 1989;245:1118–1121
  10. Nahmias C, Blin N, Elalouf JM, Mattei MG, Strosberg AD, Emorine LJ. Molecular characterization of the mouse beta 3-adrenergic receptor: relationship with the atypical receptor of adipocytes. EMBO J. 1991;10:3721–3727
  11. Nantel F, Bonin H, Emorine LJ, Zilberfarb V, Strosberg AD, Bouvier M, et al. The human beta 3-adrenergic receptor is resistant to short term agonist-promoted desensitization. Mol Pharmacol. 1993;43:548–555
  12. Zhao Q, Wu TG, Jiang ZF, Chen GW, Lin Y, Wang LX. Effect of beta-blockers on beta3-adrenoceptor expression in chronic heart failure. Cardiovasc Drugs Ther. 2007;21:85–90
  13. Hutchinson DS, Bengtsson T, Evans BA, Summers RJ. Mouse beta 3a- and beta 3b-adrenoceptors expressed in Chinese hamster ovary cells display identical pharmacology but utilize distinct signalling pathways. Br J Pharmacol. 2002;135:1903–1914
  14. Sato M, Hutchinson DS, Evans BA, Summers RJ. Functional domains of the mouse beta(3)-adrenoceptor associated with differential G-protein coupling. Biochem Soc Trans. 2007;35:5
  15. Boivin B, Lavoie C, Vaniotis G, Baragli A, Villeneuve LR, Ethier N, et al. Functional β-adrenergic receptor signalling on nuclear membranes in adult rat and mouse ventricular cardiomyocytes. Cardiovasc Res. 2006;71(1):69–78
  16. Damy T, Ratajczak P, Shah AM, Camors E, Marty I, Hasenfuss G, et al. Increased neuronal nitric oxide synthase-derived NO production in the failing human heart. Lancet. 2004;363:1365–1367
  17. Haywood GA, Tsao PS, von der Leyen HE, Mann MJ, Keeling PJ, Trindade PT, et al. Expression of inducible nitric oxide synthase in human heart failure. Circulation. 1996;93:1087–1094
  18. Massion PB, Feron O, Dessy C, Balligand JL. Nitric oxide and cardiac function: ten years after, and continuing. Circ Res. 2003;93:388–398
  19. Otani H. The role of nitric oxide in myocardial repair and remodeling. Antioxid Redox Signal. 2009;11(8):1913–1928
  20. Damy T, Ratajczak P, Robidel E, Bendall JK, Oliviéro P, Boczkowski J, et al. Up-regulation of cardiac nitric oxide synthase 1-derived nitric oxide after myocardial infarction in senescent rats. FASEB J. 2003;17(13):1934–1936
  21. Drexler H, Kästner S, Strobel A, Studer R, Brodde OE, Hasenfuss G. Expression, activity and functional significance of inducible nitric oxide synthase in the failing human heart. J Am Coll Cardiol. 1998;32(4):955–963
  22. Barouch LA, Harrison RW, Skaf MW, Rosas GO, Cappola TP, Kobeissi ZA, et al. Nitric oxide regulates the heart by spatial confinement of nitric oxide synthase isoforms. Nature. 2002;416:337–339
  23. Gauthier C, Leblais V, Kobzik L, Trochu JN, Khandoudi N, Bril A, et al. The negative inotropic effect of beta3-adrenoceptor stimulation is mediated by activation of a nitric oxide synthase pathway in human ventricle. J Clin Invest. 1998;102:1377–1384
  24. Amour J, Loyer X, Le Guen M, Mabrouk N, David JS, Camors E, et al. Altered contractile response due to increased beta3-adrenoceptor stimulation in diabetic cardiomyopathy: the role of nitric oxide synthase 1-derived nitric oxide. Anesthesiology. 2007;107:452–460
  25. Maffei A, Di Pardo A, Carangi R, Carullo P, Poulet R, Gentile MT, et al. Nebivolol induces nitric oxide release in the heart through inducible nitric oxide synthase activation. Hypertension. 2007;50:652–656
  26. Strosberg AD. Structure and function of the beta 3 adrenoreceptor. Adv Pharmacol. 1998;42:511–513
  27. Muzzin P, Seydoux J, Giacobino JP, Venter JC, Fraser C. Discrepancies between the affinities of binding and action of the novel beta-adrenergic agonist BRL 37344 in rat brown adipose tissue. Biochem Biophys Res Commun. 1988;156:375–382
  28. Bianchetti A, Manara L. In vitro inhibition of intestinal motility by phenylethanolaminotetralines: evidence of atypical beta-adrenoceptors in rat colon. Br J Pharmacol. 1990;100:831–839
  29. Dolan JA, Muenkel HA, Burns MG, Pellegrino SM, Fraser CM, Pietri F, et al. Beta-3 adrenoceptor selectivity of the dioxolane dicarboxylate phenethanolamines. J Pharmacol Exp Ther. 1994;269:1000–1006
  30. Blin N, Nahmias C, Drumare MF, Strosberg AD. Mediation of most atypical effects by species homologues of the beta 3-adrenoceptor. Br J Pharmacol. 1994;112:911–919
  31. Hoffmann C, Leitz MR, Oberdorf-Maass S, Lohse MJ, Klotz KN. Comparative pharmacology of human beta-adrenergic receptor subtypes—characterization of stably transfected receptors in CHO cells. Naunyn Schmiedebergs Arch Pharmacol. 2004;369:151–159
  32. Liggett SB. Functional properties of the rat and human beta 3-adrenergic receptors: differential agonist activation of recombinant receptors in Chinese hamster ovary cells. Mol Pharmacol. 1992;42:634–637
  33. Pietri-Rouxel F, Lenzen G, Kapoor A, Drumare MF, Archimbault P, Strosberg AD, et al. Molecular cloning and pharmacological characterization of the bovine beta 3-adrenergic receptor. Eur J Biochem. 1995;230:350–358
  34. Kubota Y, Nakahara T, Yunoki M, Mitani A, Maruko T, Sakamoto K, et al. Inhibitory mechanism of BRL37344 on muscarinic receptor-mediated contractions of the rat urinary bladder smooth muscle. Naunyn Schmiedebergs Arch Pharmacol. 2002;366:198–203
  35. Pott C, Brixius K, Bundkirchen A, Bolck B, Bloch W, Steinritz D, et al. The preferential beta3-adrenoceptor agonist BRL 37344 increases force via beta1-/beta2-adrenoceptors and induces endothelial nitric oxide synthase via beta3-adrenoceptors in human atrial myocardium. Br J Pharmacol. 2003;138:521–529
  36. Baker JG. The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors. Br J Pharmacol. 2005;144:317–322
  37. Hutchinson DS, Chernogubova E, Sato M, Summers RJ, Bengtsson T. Agonist effects of zinterol at the mouse and human beta(3)-adrenoceptor. Naunyn Schmiedebergs Arch Pharmacol. 2006;373:158–168
  38. Fisher MH, Amend AM, Bach TJ, Barker JM, Brady EJ, Candelore MR, et al. A selective human beta3 adrenergic receptor agonist increases metabolic rate in rhesus monkeys. J. Clin. Invest. 1998;101:2387–2393
  39. Kohout TA, Takaoka H, McDonald PH, Perry SJ, Mao L, Lefkowitz RJ, et al. Augmentation of cardiac contractility mediated by the human beta(3)-adrenergic receptor overexpressed in the hearts of transgenic mice. Circulation. 2001;104:2485–2491
  40. Lenzen G, Pietri-Rouxel F, Drumare MF, Amiard A, Guillot S, Archimbault P, et al. Genomic cloning and species-specific properties of the recombinant canine beta3-adrenoceptor. Eur J Pharmacol. 1998;363:217–227
  41. Arch JR. beta(3)-Adrenoceptor agonists: potential, pitfalls and progress. Eur J Pharmacol. 2002;440:99–107
  42. Arch JR, Ainsworth AT. Thermogenic and antiobesity activity of a novel beta-adrenoceptor agonist (BRL 26830A) in mice and rats. Am J Clin Nutr. 1983;38:549–558
  43. Larsen TM, Toubro S, van Baak MA, Gottesdiener KM, Larson P, Saris WH, et al. Effect of a 28-d treatment with L-796568, a novel beta(3)-adrenergic receptor agonist, on energy expenditure and body composition in obese men. Am J Clin Nutr. 2002;76:780–788
  44. van Baak MA, Hul GB, Toubro S, Astrup A, Gottesdiener KM, DeSmet M, et al. Acute effect of L-796568, a novel beta 3-adrenergic receptor agonist, on energy expenditure in obese men. Clin Pharmacol Ther. 2002;71:272–279
  45. Guimaraes S, Moura D. Vascular adrenoceptors: an update. Pharmacol Rev. 2001;53:319–356
  46. Michel MC, Vrydag W. Alpha1-, alpha2- and beta-adrenoceptors in the urinary bladder, urethra and prostate. Br J Pharmacol. 2006;147(Suppl 2):S88–S119
  47. Consoli D, Leggio GM, Mazzola C, Micale V, Drago F. Behavioral effects of the beta3 adrenoceptor agonist SR58611A: is it the putative prototype of a new class of antidepressant/anxiolytic drugs?. Eur J Pharmacol. 2007;573:139–147
  48. Stemmelin J, Cohen C, Terranova JP, Lopez-Grancha M, Pichat P, Bergis O, et al. Stimulation of the beta3-Adrenoceptor as a novel treatment strategy for anxiety and depressive disorders. Neuropsychopharmacology. 2008;33:574–587
  49. Investigators B-BEoST. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med. 2001;344:1659–1667
  50. Gan RT, Li WM, Xiu CH, Shen JX, Wang X, Wu S, et al. Chronic blocking of beta 3-adrenoceptor ameliorates cardiac function in rat model of heart failure. Chin Med J (Engl). 2007;120:2250–2255
  51. Candelore MR, Deng L, Tota L, Guan XM, Amend A, Liu Y, et al. Potent and selective human beta(3)-adrenergic receptor antagonists. J Pharmacol Exp Ther. 1999;290:649–655
  52. Niclauss N, Michel-Reher MB, Alewijnse AE, Michel MC. Comparison of three radioligands for the labelling of human beta-adrenoceptor subtypes. Naunyn Schmiedebergs Arch Pharmacol. 2006;374:99–105
  53. Brahmadevara N, Shaw AM, MacDonald A. Alpha1-adrenoceptor antagonist properties of CGP 12177A and other beta-adrenoceptor ligands: evidence against beta(3)- or atypical beta-adrenoceptors in rat aorta. Br J Pharmacol. 2004;142:781–787
  54. Briones AM, Daly CJ, Jimenez-Altayo F, Martinez-Revelles S, Gonzalez JM, McGrath JC, et al. Direct demonstration of beta1- and evidence against beta2- and beta3-adrenoceptors, in smooth muscle cells of rat small mesenteric arteries. Br J Pharmacol. 2005;146:679–691
  55. Leblais V, Pourageaud F, Ivorra MD, Marthan R, Muller B. Comparison of the alpha-adrenoceptor-mediated effects of beta3-adrenoceptor ligands in rat pulmonary artery. Naunyn Schmiedebergs Arch Pharmacol. 2005;371:535–539
  56. Horinouchi T, Koike K. Agonistic activity of SR59230A at atypical beta-adrenoceptors in guinea pig gastric fundus and duodenum. Eur J Pharmacol. 2001;416:165–168
  57. Hutchinson DS, Sato M, Evans BA, Christopoulos A, Summers RJ. Evidence for pleiotropic signaling at the mouse beta3-adrenoceptor revealed by SR59230A [3-(2-Ethylphenoxy)-1-[(1, S)-1, 2, 3, 4-tetrahydronapth-1-ylamino]-2S-2-propa nol oxalate]. J Pharmacol Exp Ther. 2005;312:1064–1074
  58. Belge C, Sekkali B, Tavernier G, Pouleur AC, Bertrand L, Vanoverschelde JL, et al. Cardiomyocyte-specific overexpression of Beta3-adrenoceptors attenuates the hypertrophic response to catecholamines in vivo. Circulation. 2007;116:II_148
  59. Morimoto A, Hasegawa H, Cheng HJ, Cheng CP. Endogenous beta3-adrenoreceptor activation contributes to left ventricular and cardiomyocyte dysfunction in heart failure. Am J Physiol Heart Circ Physiol. 2004;286:H2425–H2433
  60. Brixius K, Bloch W, Pott C, Napp A, Krahwinkel A, Ziskoven C, et al. Mechanisms of beta 3-adrenoceptor-induced eNOS activation in right atrial and left ventricular human myocardium. Br J Pharmacol. 2004;143:1014–1022
  61. Brixius K, Bloch W, Ziskoven C, Bolck B, Napp A, Pott C, et al. Beta3-adrenergic eNOS stimulation in left ventricular murine myocardium. Can J Physiol Pharmacol. 2006;84:1051–1060
  62. Massion PB, Dessy C, Desjardins F, Pelat M, Havaux X, Belge C, et al. Cardiomyocyte-restricted overexpression of endothelial nitric oxide synthase (NOS3) attenuates beta-adrenergic stimulation and reinforces vagal inhibition of cardiac contraction. Circulation. 2004;110:2666–2672
  63. Moens AL, Kass DA. Tetrahydrobiopterin and cardiovascular disease. Arterioscler Thromb Vasc Biol. 2006;26:2439–2444
  64. Fleming I, Busse R. Molecular mechanisms involved in the regulation of the endothelial nitric oxide synthase. Am J Physiol Regul Integr Comp Physiol. 2003;284:R1–R12
  65. Bauer PM, Fulton D, Boo C, Sorescu GP, Kemp BE, Jo H, et al. Compensatory phosphorylation and protein–protein interactions revealed by loss of function and gain of function mutants of multiple serine phosphorylation sites in endothelial nitric-oxide synthase. J Biol Chem. 2003;273(17):14841–14849
  66. Kou R, Greif D, Michel T. Dephosphorylation of endothelial nitric-oxide synthase by vascular endothelial growth factor. Implications for the vascular responses to cyclosporin A. J Biol Chem. 2002;277:29669–29673
  67. van der Heyden MA, Wijnhoven TJ, Opthof T. Molecular aspects of adrenergic modulation of cardiac L-type Ca2+ channels. Cardiovasc Res. 2005;65(1):28–39
  68. Xiong L, Kleerekoper QK, He R, Putkey JA, Hamilton SL. Sites on calmodulin that interact with the C-terminal tail of Cav1.2 channel. J Biol Chem. 2005;280(8):7070–7079
  69. Zhang ZS, Cheng HJ, Onishi K, Ohte N, Wannenburg T, Cheng CP. Enhanced inhibition of L-type Ca2+ current by beta3-adrenergic stimulation in failing rat heart. J Pharmacol Exp Ther. 2005;315(3):1203–1211
  70. Xu KY, Huso DL, Dawson TM, Bredt DS, Becker LC. Nitric oxide synthase in cardiac sarcoplasmic reticulum. Proc Natl Acad Sci USA. 1999;96:657–662
  71. Angelone T, Quintieri AM, Brar BK, Limchaiyawat PT, Tota B, Mahata SK, et al. The antihypertensive chromogranin a peptide catestatin acts as a novel endocrine/paracrine modulator of cardiac inotropism and lusitropism. Endocrinology. 2008;149(10):4780–4793
  72. Wang H, Kohr MJ, Traynham CJ, Wheeler DG, Janssen PM, Ziolo MT. Neuronal nitric oxide synthase signaling within cardiac myocytes targets phospholamban. Am J Physiol Cell Physiol. 2008;294(6):1566–1575
  73. Zhang YH, Zhang MH, Sears CE, Emanuel K, Redwood C, El-Armouche A, et al. Reduced phospholamban phosphorylation is associated with impaired relaxation in left ventricular myocytes from neuronal NO synthase-deficient mice. Circ Res. 2008;102(2):242–249
  74. Bendall JK, Damy T, Ratajczak P, Loyer X, Monceau V, Marty I, et al. Role of myocardial neuronal nitric oxide synthase-derived nitric oxide in beta-adrenergic hyporesponsiveness after myocardial infarction-induced heart failure in rat. Circulation. 2004;110:2368–2375
  75. Dawson D, Lygate CA, Zhang MH, Hulbert K, Neubauer S, Casadei B. nNOS gene deletion exacerbates pathological left ventricular remodeling and functional deterioration after myocardial infarction. Circulation. 2005;112:3729–3737
  76. Saraiva RM, Minhas KM, Raju SV, Barouch LA, Pitz E, Schuleri KH, et al. Deficiency of neuronal nitric oxide synthase increases mortality and cardiac remodeling after myocardial infarction: role of nitroso-redox equilibrium. Circulation. 2005;112:3415–3422
  77. Birenbaum A, Tesse A, Loyer X, Michelet P, Andriantsitohaina R, Heymes C, et al. Involvement of beta 3-adrenoceptor in altered beta-adrenergic response in senescent heart: role of nitric oxide synthase 1-derived nitric oxide. Anesthesiology. 2008;109:1045–1053
  78. Dincer UD, Bidasee KR, Guner S, Tay A, Ozcelikay AT, Altan VM. The effect of diabetes on expression of beta1-, beta2-, and beta3-adrenoreceptors in rat hearts. Diabetes. 2001;50:455–461
  79. Idigo W, Zhang MH, Zhang YH, Casadei B. The negative inotropic effect of [beta]3-adrenergic receptor stimulation in nNOS−/− mice is restored by oxypurinol. Heart. 2006;92:e1 008
  80. Khan SA, Lee K, Minhas KM, Gonzalez DR, Raju SV, Tejani AD, et al. Neuronal nitric oxide synthase negatively regulates xanthine oxidoreductase inhibition of cardiac excitation–contraction coupling. Proc Natl Acad Sci USA. 2004;101:15944–15948
  81. Shen YT, Cervoni P, Claus T, Vatner SF. Differences in beta 3-adrenergic receptor cardiovascular regulation in conscious primates, rats and dogs. J Pharmacol Exp Ther. 1996;278:1435–1443
  82. Shen YT, Zhang H, Vatner SF. Peripheral vascular effects of beta-3 adrenergic receptor stimulation in conscious dogs. J Pharmacol Exp Ther. 1994;268:466–473
  83. Lacroix JS, Kurt AM, Auberson S, Bretton C. Beta-adrenergic mechanisms in the nasal mucosa vascular bed. Eur Arch Otorhinolaryngol. 1995;252:298–303
  84. Rohrer DK, Chruscinski A, Schauble EH, Bernstein D, Kobilka BK. Cardiovascular and metabolic alterations in mice lacking both beta1- and beta2-adrenergic receptors. J Biol Chem. 1999;274:16701–16708
  85. Ignarro LJ, Byrns RE, Trinh K, Sisodia M, Buga GM. Nebivolol: a selective beta(1)-adrenergic receptor antagonist that relaxes vascular smooth muscle by nitric oxide- and cyclic GMP-dependent mechanisms. Nitric Oxide. 2002;7(2):75–82
  86. Barbe P, Millet L, Galitzky J, Lafontan M, Berlan M. In situ assessment of the role of the beta 1-, beta 2-, and beta 3-adrenoceptors in the control of liplysis and nutrive blood flow in human subcutaneous adipose tissue. Br J Pharmacol. 1996;117:907–913
  87. Larsen TM, Toubro S, van Baak MA, Gottesdiener KM, Larson P, Saris WH, et al. Effect of a 28-d treatment with L-796568, a novel beta(3)-adrenergic receptor agonist, on energy expenditure and body composition in obese men. Am J Clin Nutr. 2002;76:780–788
  88. Tagaya E, Tamaoki J, Takemura H, Isono K, Nagai A. Atypical adrenoceptor-mediated relaxation of canine pulmonary artery through a cyclic adenosine monophosphate-dependent pathway. Lung. 1999;177:321–332
  89. Tamaoki J, Tagaya E, Isono K, Nagai A. Atypical adrenoceptor-mediated relaxation of canine pulmonary artery through a cAMP-dependent pathway. Biochem Biophys Res Commun. 1998;248:722–727
  90. Oriowo MA. Atypical beta-adrenoceptors in the rat isolated common carotid artery. Br J Pharmacol. 1994;113:699–702
  91. Trochu JN, Leblais V, Rautureau Y, Beverelli F, Le Marec H, Berdeaux A, et al. Beta 3-adrenoceptor stimulation induces vasorelaxation mediated essentially by endothelium-derived nitric oxide in rat thoracic aorta. Br J Pharmacol. 1999;128:69–76
  92. Rautureau Y, Toumaniantz G, Serpillon S, Jourdon P, Trochu JN, Gauthier C. Beta 3-adrenoceptor in rat aorta: molecular and biochemical characterization and signalling pathway. Br J Pharmacol. 2002;137:153–161
  93. Kou R, Michel T. Epinephrine regulation of the endothelial nitric-oxide synthase: roles of RAC1 and beta3-adrenergic receptors in endothelial NO signaling. J Biol Chem. 2007;282:32719–32729
  94. Feldman RD. Beta-adrenergic receptor alterations in hypertension—physiological and molecular correlates. Can J Physiol Pharmacol. 1987;65:1666–1672
  95. Werstiuk ES, Lee RM. Vascular beta-adrenoceptor function in hypertension and in ageing. Can J Physiol Pharmacol. 2000;78:433–452
  96. Donckier JE, Massart PE, Van Mechelen H, Heyndrickx GR, Gauthier C, Balligand JL. Cardiovascular effects of beta 3-adrenoceptor stimulation in perinephritic hypertension. Eur J Clin Invest. 2001;31:681–689
  97. Mallem MY, Toumaniantz G, Serpillon S, Gautier F, Gogny M, Desfontis JC, et al. Impairment of the low-affinity state beta1-adrenoceptor-induced relaxation in spontaneously hypertensive rats. Br J Pharmacol. 2004;143:599–605
  98. Tavernier G, Toumaniantz G, Erfanian M, Heymann MF, Laurent K, Langin D, et al. beta3-Adrenergic stimulation produces a decrease of cardiac contractility ex vivo in mice overexpressing the human beta3-adrenergic receptor. Cardiovasc Res. 2003;59:288–296
  99. Barbier J, Mouas C, Rannou-Bekono F, Carre F. Existence of beta(3)-adrenoceptors in rat heart: functional implications. Clin Exp Pharmacol Physiol. 2007;34:796–798
  100. Cheng HJ, Zhang ZS, Onishi K, Ukai T, Sane DC, Cheng CP. Upregulation of functional beta(3)-adrenergic receptor in the failing canine myocardium. Circ Res. 2001;89:599–606
  101. Kitamura T, Onishi K, Dohi K, Okinaka T, Isaka N, Nakano T. The negative inotropic effect of beta3-adrenoceptor stimulation in the beating guinea pig heart. J Cardiovasc Pharmacol. 2000;35:786–790
  102. Skeberdis VA, Gendviliene V, Zablockaite D, Treinys R, Macianskiene R, Bogdelis A, et al. beta3-adrenergic receptor activation increases human atrial tissue contractility and stimulates the L-type Ca2+ current. J Clin Invest. 2008;118:3219–3227
  103. Takayama S, Furukawa Y, Ren LM, Inoue Y, Sawaki S, Chiba S. Positive chronotropic and inotropic responses to BRL 37344, a beta 3-adrenoceptor agonist in isolated, blood-perfused dog atria. Eur J Pharmacol. 1993;231:315–321
  104. Imbrogno S, Angelone T, Adamo C, Pulera E, Tota B, Cerra MC. Beta3-adrenoceptor in the eel (Anguilla anguilla) heart: negative inotropy and NO-cGMP-dependent mechanism. J Exp Biol. 2006;209:4966–4973
  105. Au AL, Kwan YW. Modulation of L-type Ca2+ channels by beta3-adrenoceptor activation and the involvement of nitric oxide. J Card Surg. 2002;17:465–469
  106. Moniotte S, Balligand JL. Potential use of beta(3)-adrenoceptor antagonists in heart failure therapy. Cardiovasc Drug Rev. 2002;20:19–26
  107. Rozec B, Noireaud J, Trochu JN, Gauthier C. Place of beta 3-adrenoceptors among other beta-adrenoceptor subtypes in the regulation of the cardiovascular system. Arch Mal Coeur Vaiss. 2003;96:905–913
  108. Napp A, Brixius K, Pott C, Ziskoven C, Boelck B, Mehlhorn U, et al. Effects of the beta3-adrenergic agonist BRL 37344 on endothelial nitric oxide synthase phosphorylation and force of contraction in human failing myocardium. J Card Fail. 2009;15:57–67
  109. Ziskoven C, Grafweg S, Bolck B, Wiesner RJ, Jimenez M, Giacobino JP, et al. Increased Ca2+ sensitivity and protein expression of SERCA 2a in situations of chronic beta3-adrenoceptor deficiency. Pflugers Arch. 2007;453:443–453
  110. Wagner KD, Geil D, Schimke I, Stauss HM, Lammerich A, Theres H, et al. Decreased susceptibility of contractile function to hypoxia/reoxygenation in chronic infarcted rat hearts. J Mol Cell Cardiol. 1998;30:2341–2353
  111. Cross HR, Steenbergen C, Lefkowitz RJ, Koch WJ, Murphy E. Overexpression of the cardiac beta(2)-adrenergic receptor and expression of a beta-adrenergic receptor kinase-1 (betaARK1) inhibitor both increase myocardial contractility but have differential effects on susceptibility to ischemic injury. Circ Res. 1999;85:1077–1084
  112. Engelhardt S, Hein L, Keller U, Klambt K, Lohse MJ. Inhibition of Na(+)-H(+) exchange prevents hypertrophy, fibrosis, and heart failure in beta(1)-adrenergic receptor transgenic mice. Circ Res. 2002;90:814–819
  113. Rozec B, Erfanian M, Laurent K, Trochu JN, Gauthier C. Nebivolol, a vasodilating selective beta(1)-blocker, is a beta(3)-adrenoceptor agonist in the nonfailing transplanted human heart. J Am Coll Cardiol. 2009;53(17):1532–1538
  114. Moens AL, Leyton-Mange JS, Niu X, Yang R, Cingolani O, Arkenbout EK, et al. Adverse ventricular remodeling and exacerbated NOS uncoupling from pressure-overload in mice lacking the beta3-adrenoreceptor. J Mol Cell Cardiol 2009;47(5):576–85.

PII: S0022-2828(10)00046-5

doi: 10.1016/j.yjmcc.2010.02.011

Journal of Molecular and Cellular Cardiology
Volume 48, Issue 6 , Pages 1088-1095 , June 2010

Article Tools